This trial is testing whether combining two drugs, rucaparib and nivolumab, may be effective in treating leiomyosarcoma (LMS), a type of cancer.
1 Primary · 1 Secondary · Reporting Duration: at 24 weeks
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Rucaparib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: